医学と薬学　71/1　2014年1月号

出版社： 自然科学社
発行日： 2013-12-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 糖尿病をめぐる話題と治療の現況
電子書籍版： 2013-12-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,100 円(税込)

購入する

目次

  • 表紙
  • 目次
  • 【特集 糖尿病をめぐる話題と治療の現況】
  • 糖尿病の分類と診断基準
  • 糖尿病の疫学 - 観察研究の成績から
  • 新しい治療目標 - 熊本宣言2013
  • 治療
  • 経口血糖降下薬
  • インスリン / GLP - 1受容体作動薬
  • 新規治療薬開発の状況
  • 食事療法
  • 合併症対策
  • 糖尿病網膜症
  • 糖尿病腎症
  • 糖尿病合併高血圧
  • 糖尿病神経障害
  • 【総説】
  • 新規作用機序を持つSGLT2阻害薬に対する期待
  • 【研究会】
  • 第46回 間脳下垂体疾患研究会
  • [ 一般演題I ]
  • 1. 下垂体負荷試験後に急性副腎不全を呈したラトケ嚢胞の1例
  • 2. カベルゴリン2回投与で気脳症をきたしたMEN1型合併マクロプロラクチノーマ
  • 3. 思春期Childhood Cancer Survivorsの自験例の検討
  • [ 一般演題II ]
  • 4. 当院で経験したクッシング病の5例
  • 5. 妊娠中に頭痛, 動眼神経麻痺で発症した下垂体腺腫の1例
  • 6. 重症型成人成長ホルモン分泌不全症例に対するGH治療
  • 【研究】
  • 各種ウイルスに対する新規速乾性すり込み式手指消毒薬の有効性評価
  • 【薬剤】
  • アトルバスタチン製剤の種々の保存条件下での溶出性の評価研究
  • 【臨床報告】
  • エキセナチド週1回製剤とDTSQを用いた患者治療満足度
  • 【Diagnosis】
  • Chemiluminescent enzyme immunoassay ( CLEIA ) 法を用いたトキソプラズマ抗体測定試薬の基礎的検討
  • 化学発光酵素免疫測定法を原理とする「ステイシアCLEIA HBs抗体」の基本性能
  • 全自動免疫測定装置HISCL - 5000を用いたSP - A測定試薬の基礎的検討
  • 【巻末付録】
  • 学会・研究会開催予定 ( 2014年1月～3月 )
  • 編集顧問
  • 人名索引
  • キーワード索引
  • ご投稿案内
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 糖尿病をめぐる話題と治療の現況】

P.13 掲載の参考文献
1) 清野裕, 南條輝志男, 田嶼尚子 他 : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 53 : 450-467, 2010.
 
2) 清野裕, 南條輝志男, 田嶼尚子 他 : 糖尿病の分類と診断基準に関する委員会報告 (国際標準化対応版). 糖尿病 55 : 485-504, 2012.
 
3) Imagawa A, Hanafusa T, Miyagawa J et al : A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med. 342 : 301-307, 2000.
 
4) Fajans SS : Scope and heterogeneous nature of MODY. Diabetes Care 13 : 49-64, 1990.
PubMed
5) Kadowaki T, Kadowaki H, Mori Y et al : A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 330 : 962-968, 1994.
PubMed
6) Kadowaki T, Bevins CL, Cama A et al : Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 240 : 787-790, 1988.
 
7) Kosaka K, Hagura R, Kuzuya T et al : Insulin secretory response of diabetics during the period of improvement of glucose tolerance to normal range. Diabetologia 10 : 775-782, 1974.
PubMed
8) Seino Y, Kurahachi H, Goto Y et al : Comparative insulinogenic effects of glucose, arginine and glucagon in patients with diabetes mellitus, endocrine disorders and liver disease. Acta Diabetol Lat 12 : 89-99, 1975.
PubMed
9) Metzger BE, Lowe LP, Dyer AR et al : Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 358 : 1991-2002, 2008.
PubMed
10) IADPSG Consensus Panel : International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33 : 676-682, 2010.
 
P.21 掲載の参考文献
1) Diabetes Epidemiology Research International Mortality Study Group. Major cross-country differences in risks of dying for people with IDDM. Diabetes Care 14 : 49-54, 1991.
 
2) Diabetes Epidemiology Research International Mortality Study Group. International analysis of insulin-dependent diabetes mellitus mortality : a preventable mortality perspective. Am J Epidemiol 142 : 612-618, 1995.
 
3) Nishimura R, Matsushima M, Tajima N et al. A major improvement in the prognosis of individuals with IDDM in the past 30 years in Japan. The Diabetes Epidemiology Research International Study Group. Diabetes Care 19 : 758-760, 1996.
 
4) Morimoto A, Onda Y, Nishimura R et al. Cause-specific mortality trends in a nationwide population-based cohort of childhood-onset type 1 diabetes in Japan during 35 years of follow-up : the DERI Mortality Study. Diabetologia 56 : 2171-2175, 2013.
 
5) Takeda H, Kawasaki E, Shimizu I et al : Clinical autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 25 : 995-1001, 2002.
PubMed
6) Murao S, Makino H, Kaino Y et al : Differences in the contribution of HLA-DR and-DQ haplotypes to susceptibility to adult-and childhood-onset type 1 diabetes in Japanese patients. Diabetes Care 53 : 2684-2690, 2004
 
7) 厚生労働省 : 平成23年国民健康・栄養調査.
Medical*Online
8) Hata J, Ninomiya T, Hirakawa Y et al : Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961-2009). Circulation 128 : 1198-1205, 2013.
PubMed
9) 伊藤千賀子: 耐糖能異常 (IGT) ・境界型の自然史. 日本臨床 63 (増刊号 2) : 63-66, 2005.
 
10) Kuzuya T, Akanuma Y, Akazawa Y et al : Prevalence of chronic complications in Japanese diabetic patients. Diabetes Res ClinPract Suppl : S159-S164, 1994.
 
11) Kato S, Takemori M, Kitano S et al : Retinopathy in older patients with diabetes mellitus. Diabetes Res ClinPract 58 : 187-192, 2002.
PubMed
12) Kawasaki R, Tanaka S, Tanaka S et al : Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study. Diabetologia 54 : 2288-2294, 2011.
PubMed
13) 日本透析医学会 : わが国の慢性透析両方の現況.
 
14) Yokoyama H, Kawai K, Kobayashi M : Japan Dia betes Clinical Data Management Study Group. Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). Diabetes Care 30 : 989-992, 2007.
 
15) 石井晶子, 大竹瑞穂, 馬場園哲他 : 糖尿病 より厳格な管理の実際 糖尿病性腎症の早期管理の重要性とその実際. Med Pract 18 : 1647-1651, 2001.
 
16) Yamada T, Komatsu M, Komiya I et al : Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control : the Kashiwa study. Diabetes Care 28 : 2733-2738, 2005.
PubMed
17) 日本臨床内科医会調査研究グループ : 糖尿病神経障害に関する調査研究 第2報 糖尿病神経障害. 日本臨床内科医会会誌 16 : 353-381, 2001.
 
18) Sone H, Tanaka S, Tanaka S et al : Serum level of Triglycerides Is a Potential Risk Factor Comparable to LDL Cholesterol for Coronary Heart Disease in Japanese Patients with Type 2 Diabetes : Subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 96 : 3448-3456, 2011.
 
19) Tominaga M, Eguchi H, Manaka H et al : Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 : 920-924, 1999. The DECODE study group. Glucose tolerance and mortality : comparison of WHO and AmericanDiabetic Association diagnostic criteria. Lancet 354 : 617-621, 1999.
PubMed
20) 糖尿病と癌に関する委員会 : 糖尿病と癌に関する委員会報告. 糖尿病 56 : 374-390, 2013.
 
21) Hirakawa Y, Ninomiya T, Mukai N et al : Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study. Am J Epidemiol 176 : 856-864, 2012.
 
22) Ohara T, Doi Y, Ninomiya T, Hirakawa Y et al : Glucose tolerance status and risk of dementia in the community : the Hisayama study. Neurology 77 : 1126-1134, 2011.
PubMed
23) 日本膵臓学会. 膵癌診療ガイドライン2009年度版. 金原出版, 東京, 2009.
 
24) Whitmer RA, Karter AJ, Yaffe K et al : Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301 : 1565-1572, 2009.
PubMed
P.26 掲載の参考文献
1) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン2013, pp.21-30, 南江堂, 東京, 2013.
 
2) 日本糖尿病学会編. 糖尿病治療ガイド2012-2013 血糖コントロール目標改訂版, pp.24-38, 文光堂, 東京, 2013.
 
P.33 掲載の参考文献
1) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 : 854-865, 1998.
PubMed
2) Knowler WC, Barrett-Connor E, Fowler SE et al : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 : 393-403, 2002.
 
3) Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM : New users of metformin are at low risk of incident cancer : a cohort study among people with type 2 diabetes. Diabetes Care 32 : 1620-1625, 2009.
 
4) Noto H, Goto A, Tsujimoto T, Noda M : Cancer risk in diabetic patients treated with metformin : a systematic review and meta-analysis. PLoS One 7 : e33411, 2012.
PubMed
5) Kahn SE, Haffner SM, Heise MA et al : Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 : 2427-2443, 2006.
PubMed
6) Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 366 : 1279-1289, 2005.
PubMed
7) Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn AR, Perez A : Observational follow-up of the PROactive study : a 6-year update (+). Diabetes Obes Metab 2013.
PubMed
8) Tseng CH. Pioglitazone and bladder cancer : a population-based study of Taiwanese. Diabetes Care 35 : 278-280, 2012.
PubMed
9) Gonzalez-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R et al : Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications 23 : 376-379, 2009.
PubMed
10) Cobitz AR, Ambery P : Medical management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Response to Nathan et al. Diabetes Care 32 : e58, author rely e9, 2009.
 
11) Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F : The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas : a systematic review and meta-analysis. Diabetes Metab Res Rev 2013.
 
12) Wang L, Guo L, Zhang L et al : Effects of glucose load and nateglinide intervention on endothelial function and oxidative stress. J Diabetes Res 2013 : 849295, 2013.
PubMed
13) Li J, Tian H, Li Q et al : Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 9 : 558-565, 2007.
 
14) Holman RR, Haffner SM, McMurray JJ et al : Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362 : 1463-1476, 2010.
PubMed
15) Schramm TK, Gislason GH, Vaag A et al : Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction : a nationwide study. Eur Heart J 32 : 1900-1908, 2011.
PubMed
16) Glucose tolerance and mortality : comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology : Collaborative analysis of Diagnostic criteria in Europe. Lancet 354 : 617-621, 1999.
 
17) Chiasson JL, Josse RG, Gomis R et al : Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial. Lancet 359 : 2072-2077, 2002.
PubMed
18) Chiasson JL, Josse RG, Gomis R et al : Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 290 : 486-494, 2003.
PubMed
P.43 掲載の参考文献
1) Hemmingsen B, Lund SS, Gluud C et al : Intensive glycaemic control for patients with type 2 diabetes : systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343 : d6898, 2011.
PubMed
2) Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al : Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes : meta-analysis of randomised controlled trials. BMJ 343 : d4169, 2011.
PubMed
3) Group AS, Gerstein HC, Miller ME et al : Longterm effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364 : 818-28, 2011.
 
4) Ismail-Beigi F, Craven T, Banerji MA et al : Ef fect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes : an analysis of the ACCORD randomised trial. Lancet 376 : 419-430, 2010.
 
5) Nathan DM, Cleary PA, Backlund JY et al : Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 : 2643-2653, 2005.
PubMed
6) Holman RR, Paul SK, Bethel MA et al : 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 : 1577-1589, 2008.
PubMed
7) Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME et al : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545-2559, 2008.
 
8) Duckworth W, Abraira C, Moritz T et al : Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 : 129-139, 2009.
PubMed
9) Group AC, Patel A, MacMahon S et al : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 : 2560-2572, 2008.
 
10) Bonds DE MM, Bergenstal RM, Buse JB et al : The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes : retrospective epidemiological analysis of the ACCORD study. BMJ 340 : b4909, 2010.
PubMed
11) Zoungas S, Patel A, Chalmers J et al : Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363 : 1410-1418, 2010.
PubMed
12) Johnston SS, Conner C, Aagren M et al : Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 34 : 1164-1170, 2011.
 
13) Desouza C, Salazar H, Cheong B et al : Association of hypoglycemia and cardiac ischemia : a study based on continuous monitoring. Diabetes Care 26 : 1485-1489, 2003.
PubMed
14) Laitinen T, Lyyra-Laitinen T, Huopio H et al : Electrocardiographic alterations during hyperinsulinemic hypoglycemia in healthy subjects. Ann Noninvasive Electrocardiol 13 : 97-105, 2008.
PubMed
15) Whitmer RA, Karter AJ, Yaffe K et al : Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301 : 1565-1572, 2009.
PubMed
16) Holman RR, Farmer AJ, Davies MJ et al : Threeyear efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361 : 1736-1747, 2009.
PubMed
17) Holman RR, Thorne KI, Farmer AJ et al : Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357 : 1716-1730, 2007.
PubMed
18) Ratner RE, Gough SC, Mathieu C et al : Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes : a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 15 : 175-184, 2013.
PubMed
19) Hirsch IB, Bode B, Courreges JP et al : Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes : a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care 35 : 2174-2181, 2012.
PubMed
20) Niskanen L, Leiter LA, Franek E et al : Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes : a randomised trial. Eur J Endocrinol 167 : 287-294, 2012.
PubMed
21) Edie ES : Further Observations on the Treatment of Diabetes Mellitus by Acid Extract of Duodenal Mucous Membrane. Biochem J 1 : 446-454, 1906.
PubMed
22) Bell GI, Sanchez-Pescador R, Laybourn PJ et al : Exon duplication and divergence in the human preproglucagon gene. Nature 304 : 368-371, 1983.
PubMed
23) Meier JJ : GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 : 728-742, 2012.
PubMed
24) Marre M, Shaw J, Brandle M et al : Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 26 : 268-278, 2009.
PubMed
25) Nauck M, Frid A, Hermansen K et al : Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes : the LEAD (liraglutide effect and action in diabetes) -2 study. Diabetes Care 32 : 84-90, 2009.
PubMed
26) Garber A, Henry R, Ratner R et al : Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono) : a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 : 473-481, 2009.
 
27) Zinman B, Gerich J, Buse JB et al : Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32 : 1224-1230, 2009.
PubMed
28) Russell-Jones D, Vaag A, Schmitz O et al : Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU) : a randomised controlled trial. Diabetologia 52 : 2046-2055, 2009.
 
29) Buse JB, Rosenstock J, Sesti G et al : Liraglutide once a day versus exenatide twice a day for type 2 diabetes : a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 : 39-47, 2009.
 
30) Seino Y, Rasmussen MF, Nishida T et al : Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 26 : 1013-22, 2010.
PubMed
31) Kaku K, Rasmussen MF, Clauson P et al : Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 12 : 341-347, 2010.
PubMed
32) Peterson G : Current treatments and strategies for type 2 diabetes : can we do better with GLP-1 receptor agonists? Ann Med 44 : 338-349, 2012.
PubMed
33) Grimm M, Han J, Weaver C et al : Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus : an integrated analysis of the DURATION trials. Postgrad Med 125 : 47-57, 2013.
PubMed
34) Petersen AB, Christensen M : Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndr Obes 6 : 217-231, 2013.
PubMed
35) Horowitz M, Rayner CK, Jones KL : Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther 30 : 81-101, 2013.
PubMed
36) Marathe CS, Rayner CK, Jones KL et al : Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 36 : 1396-1405, 2013.
PubMed
37) Morrow L, Hompesch M, Guthrie H et al : Coadministration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab 13 : 75-80, 2011.
PubMed
38) Buse JB, Bergenstal RM, Glass LC et al : Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes : a randomized, controlled trial. Ann Intern Med 154 : 103-112, 2011.
PubMed
P.55 掲載の参考文献
1) Marsenic O. Glucose control by the kidney : an emerging target in diabetes. Am J Kidney Dis 53 : 875-883, 2009.
PubMed
2) Wright EM, Hirayama BA, Loo DF : Active sugar transport in health and disease. J Intern Med 261 : 32-43, 2007.
 
3) Kanai Y, Lee WS, You G et al : The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93 : 397-404, 1994.
PubMed
4) Idris I, Donnelly R : Sodium-glucose co-transporter-2 inhibitors : an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 11 : 79-88, 2009
PubMed
5) Gerich JE : Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus : therapeutic implications. Diabet Med 27 : 136-142, 2010.
PubMed
6) Bailey CJ, Gross JL, Pieters A et al : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin : a randomised, double-blind, placebocontrolled trial. Lancet 375 (9733) 2223-2233, 2010.
PubMed
7) Kaku K, Inoue S, Matsuoka O et al : Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control : a Phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obest Metab 5 (5) : 432-440, 2013.
 
8) Sawzdrgo M, George SR, Nguyen T et al : A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem Biophys Res Commun 239 : 543-547, 1997.
 
9) Hamid YH, Vissing H, Holst B et al : Studies of relationships between variation of the human G protein-coupled receptor 40 Gene and Type 2 diabetes and insulin release. Diabet Med 22 : 74-80, 2005.
 
10) Briscoe CP, Tadayyon M, Andrews JL et al : The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278 : 11303-11311, 2003.
PubMed
11) Itoh Y, Kawamata Y, Harada M et al : Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature 422 : 173-176, 2003.
 
12) Hirasawa A, Itsubo C, sadakane K et al : Production and characterization of a monoclonal antibody against GPR40 (FFAR1; free fatty acid receptor 1). Biochem Biophys Res Commun 365 : 22-28, 2008.
PubMed
13) Christopher J, Murthy SR, Viviane DA et al : Fatty Acid Signaling in the β-Cell and Insulin Secretion. Diabetes 55 suppl 2 : S16-S23, 2006.
 
14) Feng DD, Luo Z, Roh S et al : Reduction in Voltage-Gated K+ Currents in Primary Cultured Rat Pancreatic β-Cells by Linoleic Acids. Endocrinology 147 : 674-682, 2006.
 
15) Ferdaoussi M, Bergeron V, Zarrouki B et al : G protein-coupled receptor (GPR) 40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 55 : 2682-2692, 2012.
PubMed
16) Edfalk S, Steneberg P, Edlund H et al : GPR40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion. Diabetes 57 : 2280-2287, 2008
PubMed
17) Burant CF, Viswanathan P, Marcinak J et al : TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus : a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379 (9824) : 1403-1411, 2012.
PubMed
18) Kaku K, Araki T, Yoshinaka R : Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 36 : 245-250, 2013.
PubMed
19) Grimsby J, Sarabu R, Corbett WL et al : Allosteric activators of glucokinase : potential role in diabetes therapy. Science 301 : 370-373, 2003.
PubMed
20) Meininger GE, Scott R, Alba M et al : Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34 : 2560-2566, 2011.
PubMed
21) Soga T, Ohishi T, Matsui T et al : Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 326 : 744-751, 2005.
PubMed
22) Wright EM, Hirayama BA, Loo DF : Active sugar transport in health and disease. J Intern Med 261 : 32-43, 2007.
 
23) Katz LB, Gambale JJ, Rothenberg PL et al : Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab 14 : 709-716, 2012.
 
24) Oh da Y, Talukdar S, Bae EJ et al : GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142 : 687-698, 2010.
PubMed
25) Ichimura A, Hirasawa A, Poulain-Godefroy O et al : Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483 : 350-354, 2012.
PubMed
26) Qureshi SA, Candelore MR, Xie D et al : Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects. Diabetes 53 : 3257-3273, 2004.
 
27) Lee Y, Wang MY, Du XQ et al : Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice. Diabetes 60 : 391-397, 2011.
 
28) Rosenstock J, Banarer S, Fonseca VA et al : The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33 : 1516-1522, 2010.
PubMed
29) Hollis G, Huber R : 11beta-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab 13 : 1-6, 2011.
PubMed
P.65 掲載の参考文献
1) 日本糖尿病学会編集 : 3. 食事療法, 科学的根拠に基づく糖尿病診療ガイドライン2013, pp.31-46, 南江堂, 東京, 2013.
 
2) 厚生労働省: 平成22年国民健康・栄養調査結果の概要
 
3) Fung TT et al : Low-carbohydrate diets and allcause and cause-specific mortality : two cohort studies. Ann Intern Med 153 : 289-298, 2010.
PubMed
4) Standards of medical care in diabetes-2012. Diabetes Care 35 (suppl 1) : S11-63, 2012.
 
5) S.Y.Foo et al : Vascular effects of a lowcarbohydrate high-protein diet. Proc Natl Acad Sci USA 106 : 15418-15423, 2009.
 
6) de Koning L et al : Low-carbohydrate diet scores and risk of type 2 diabetes in men. Am J Clin Nutr 93 : 844-850, 2011.
PubMed
7) E. R. Pearson : Translating TCF7L2 : from gene to function. Diabetologia 52 : 1227-1230, 2009.
 
8) J C. Florez et al : TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. N Engl J Med 355 : 241-250, 2006.
 
9) J Buteau et al : Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass. Diabetes 55 : 1190-1196, 2006.
 
10) E. Mukai et al : Exendin-4 suppresses Src activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epacdependent manner. Diabetes 60 : 218-226, 2011.
 
P.70 掲載の参考文献
1) Yamashita H : International clinical diabetic retinopathy and diabetic macular edema disease severity scales. Nihon Ganka Gakkai Zasshi 107 : 110-113, 2003.
PubMed
2) Wilkinson CP, Ferris FL 3rd, Klein RE et al : Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110 : 1677-1682, 2003.
PubMed
3) The Diabetes Control and Complications Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 : 977-986, 1993.
 
4) Ohkubo Y, Kishikawa H, Araki E et al : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 28 : 103-117, 1995.
PubMed
5) United Kingdom Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 : 837-853, 1998.
 
6) United Kingdom Prospective Diabetes Study (UKPDS) Group : Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes : UKPDS 38. BMJ 317 : 703-713, 1998.
 
7) 日本糖尿病学会 : 糖尿病網膜症の治療. 科学的根拠に基づく糖尿病診療ガイドライン 2013, pp.85-95, 南江堂, 東京, 2013.
 
8) Kwiterovich KA, Maguire MG, Murphy RP et al : Frequency of adverse systemic reactions after fluorescein angiography. Results of a prospective study. Ophthalmology 98 : 1139-1142, 1991.
PubMed
9) Sanghvi C, McLauchlan R, Delgado C et al : Initial experience with the Pascal photocoagulator : a pilot study of 75 procedures. Br J Ophthalmol 92 : 1061-1064, 2008.
PubMed
10) 西塚弘一 : 【網膜硝子体疾患診療の進歩2012】治療手技の進歩 硝子体手術の進歩 内視鏡を用いた硝子体手術. あたらしい眼科 29 : 204-208, 2012.
 
11) 後藤早紀子 : 【糖尿病と糖尿病網膜症】糖尿病黄斑浮腫の治療戦略. あたらしい眼科 27 : 1217-1221, 2010.
 
12) Early Treatment Diabetic Retinopathy Study research group : Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (12) : 1796-806, 1985.
 
13) Yamamoto T, Takeuchi S, Sato Y et al : Longterm follow-up results of pars plana vitrectomy for diabetic macular edema. Jpn J Ophthalmol 51 : 285-291, 2007.
PubMed
P.79 掲載の参考文献
1) 猪股茂樹, 羽田勝計, 守屋達美他 : 糖尿病性腎症の新しい診断基準. 糖尿病 48 : 757-759, 2005.
 
2) Perkins BA, Ficociello LH, Ostrander BE et al : Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 18 : 1353-1361, 2007.
PubMed
3) Adler AI, Stevens RJ, Manley SE et al : Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 : 225-231, 2003.
PubMed
4) Gaede P, Vedel P, Larsen N et al : Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 : 383-393, 2003.
PubMed
5) Gaede P, Lund-Andersen H, Parving HH et al : Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 : 580-591, 2008.
PubMed
6) 滋賀県医師会糖尿病実態調査委員会. 滋賀県内全医療機関を対象とした糖尿病実態調査-平成12年と18年の比較から-. 日本医事新報 4399 : 71-74, 2008.
 
7) Fioretto P, Mauer M, Brocco E et al : Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39 : 1569-1576, 1996.
PubMed
8) Araki S, Haneda M, Koya D et al : Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care 33 : 1805-1810, 2010.
PubMed
9) Araki S, Haneda M, Koya D, et al : Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 36 : 1248-1253, 2013.
PubMed
10) Matsuo S, Imai E, Horio M, Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53 : 982-992, 2009.
PubMed
11) 日本腎臓学会編 : CKD診療ガイド2012, 東京医学社, 東京, 2012.
 
12) Horio M, Imai E, Yasuda Y et al : GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis 61 : 197-203, 2013.
PubMed
13) DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365 : 2366-2376, 2011.
 
14) Coca SG, Ismail-Beigi F, Haq N et al : Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus : systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172 : 761-769, 2012.
PubMed
15) Perkovic V, Heerspink HL, Chalmers J et al : Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83 : 517-523, 2013.
PubMed
16) Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M : Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339 : 69-75, 1998.
PubMed
17) Araki S, Haneda M, Sugimoto T et al : Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes mellitus. Diabetes 54 : 2983-2987, 2005.
PubMed
18) de Galan BE, Perkovic V, Ninomiya T et al : Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 20 : 883-892, 2009.
PubMed
19) Yokoyama H, Araki S, Honjo J et al : Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care 36 : 3227-3233, 2013.
PubMed
P.89 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン2009, pp.63-66, ライフサイエンス出版, 東京, 2009.
 
2) The ACCORD Study Group : Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 362 : 1575-1585, 2010.
 
3) Cooper-DeHoff RM, Gong Y, Handberg EM et al : Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304 : 61-68, 2010.
PubMed
4) Haller H, Ito S, Izzo JL et al : Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364 : 907-917, 2011.
 
5) Banglore S, Kumar S, Lobach I et al : Blood Pressure Targets With Type 2 Diabetes Mellitus/Impaired Fasting Glucose : Observations From Traditional and Bayesian Random-Effects Meta-Analysis of Randomized Trials. Circulation 123 : 2799-2810, 2011.
 
6) American Diabetes Association : Standards of Medical Care in Diabetes-2013. Diabetes Care 36 (suppl 1) : S11-S66, 2013.
 
7) The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), J Hypertens 31 : 1281-1357 2013.
 
8) Daskalopouou SS, Khan N, Quinn RR et al.: The 2012 Canadian Hypertension Education Program recommemndations for the management of hypertension : Blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 28 : 270-287, 2012.
 
9) Asayama K, Ohkubo T, Metoki H et al : Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertens Res 35 : 1102-1110, 2012.
PubMed
10) Noguchi Y, Asayama K, Staessen JA et al : Predictive power of home blood pressure and clinic blood pressure in hypertensive patients with impaired glucose metabolism and diabetes. J Hypertens 31 : 1593-1602, 2013.
PubMed
11) Jamerson K, Weber M, Bakris et al : Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 : 2417-2428, 2008.
 
P.100 掲載の参考文献
1) Consensus statement : Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 11 (1) : 592-597, 1988.
 
2) Tesfaye S, Boulton AJ, Dyck PJ et al : Diabetic neuropathies : Update on definitions, diagnostic criteria, estimation of severity, and treatment. Diabetes Care 33 : 2283-2293, 2010.
 
3) Tesfaye S : Recent advance in the management of diabetic distal symmetric polyneuropathy. J Diabetes Invest 2 : 33-42, 2011.
 
4) Massie R, Mauermann ML, Staff NP et al : Diabetic cervical radiculoplexus neuropathy : a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain 135 : 3074-3088, 2012.
PubMed
5) Gibbons CH, Freeman R : Treatment-induced diabetic neuropathy : A reversible painful autonomic neuropathy. Ann Neurol 67 : 534-541, 2010.
PubMed
6) Boulton AJM, Malik RA, Arezzo JC et al : Diabetic somatic neuropathies. Diabetic Care 27 : 1458-1486, 2004.
PubMed
7) Vinik AI, Maser RE, Mitchell BD et al : Diabetic autonomic neuropathy. Diabetes Care 26 : 1553-1579, 2003.
PubMed
8) 糖尿病性神経障害を考える会 : 糖尿病性多発神経障害の簡易診断基準の改定について. 末梢神経 14 : 225-227, 2003.
 
9) Yasuda H, Sanada M, Kitada K et al : Rational and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract 77 (Suppl 1) : S178-183, 2007.
 
10) 糖尿病性神経障害を考える会 : 簡易診断基準もとにした糖尿病性多発神経障害の病期分類の公表にあたって. 末梢神経 21 : 372-373, 2010.
 
11) Ogawa K, Sasaki H, Yamasaki H et al : Peripheral nerve functions may deteriorate parallel to the progression of microangiopathy in diabetic patients. Nutr Metab Cardiovasc Dis 16 : 313-321, 2005.
 
12) Lauria G, Cornblath DR, Johansson O et al : EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 12 : 747-758, 2005
PubMed
13) Tavakoli M, Quattrini C, Abbott C et al : Corneal confocal microscopy : a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 38 (8) : 1792-1797, 2010.
 
14) Arimura A, Deguchi T, Sugimoto K et al : Intraepidermal nerve fiber density and nerve conduction study parameters correlate with clinical staging of diabetic polyneuropathy. Diabetes Res Clin Pract 99 (1) : 24-29, 2013.
PubMed
15) Tavakoli M, Mitu-Pretorian M, Petropoulos IN et al : D Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. Diabetes 62 (1) : 254-260, 2013.
 
16) The Diabetes Control and Complication Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of neuropathy. Ann Inter Med 122 : 561-568, 1995.
 
17) Ohkubo Y, Kishikawa H, Araki E et al : Intensive insulin therapy prevents the progression of diabetic microvascular complications of in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 28 : 103-117, 1995.
PubMed
18) Hotta N, Akamuma Y, Kawamori R et al : Longterm clinical effects of eparlestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 29 : 1538-1545, 2006.
 
19) Hotta N, Kawamori R, Fukuda M et al : Longterm clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications : multivariate epidemiological analysis based on patients background factors and severity of diabetic neuropathy. Diabet Med 29 : 1529-1533, 2012.
PubMed
20) Yasuda H, Hotta N, Nakao K et al : Superiority of duloxetine to placebo in improving diabetic neuropathic pain : Results of a randomized controlled trial in Japan. J Diabetes Invest 2 : 132-139, 2011.
 
21) Satoh J, Yagkhashi S, Baba M et al : Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy : a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med 28 : 109-116, 2011.
 
22) Ziegler D : Painful diabetic neuropathy : advantage of novel drugs over old drugs? Diabetes Care 32 (Suppl 2) : S414-419, 2009.
 
23) Boulton, AJM.: Treatment of painful diabetic neuropathy. Diabetic neuropathy Clinical management 2nd. (ed. by Veves A, Malik RA), pp.351-365, Humana Press, New Jersey, 2007.
 

【総説】

P.109 掲載の参考文献
1) IDF : Diabetes Atlas 5th edition. International Diabetes Federation, 2012. http://www.idf.org/diabetesatlas
 
2) 厚生労働省 : 平成23年国民健康・栄養調査報告. http://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h23-houkoku.pdf
 
3) 国立循環器病研究センターホームページ : 糖尿病実態アンケート調査結果. http://www.ncvc.go.jp/
 
4) 坂井建雄 : 初心者のための腎臓の構造. 日腎会誌 43 (7) : 572-579, 2001.
 
5) 坂井建雄, 河原克雅 : カラー図解人体の正常構造と機能 5巻 腎・泌尿器, 第2版, pp.13, 日本医事新報社, 東京, 2012.
 
6) Wright EM, Hirayama BA, Loo DF : Active sugar transport in health and disease. J Intern Med 261 (1) : 32-43, 2007.
 
7) Bays H : From victim to ally : the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 25 (3) : 671-681, 2009.
PubMed
8) 大野晴也, 浅野知一郎 : 新しい糖尿病治療薬 8, SGLT2阻害薬の現状と展望. 月刊糖尿病 3 (1) : 108-113, 2011.
 
9) Marsenic O : Glucose control by the kidney : an emerging target in diabetes. Am J Kidney Dis 53 (5) : 875-883, 2009.
PubMed
10) 山下陽子, 山本憲朗, 芦田均 : ポリフェノールによるグルコーストランスポーターの機能調節. ビタミン 86 (3) : 163-173, 2012.
Medical*Online
11) 竹田孔明, 谷澤幸生 : SGLT2阻害薬への期待, 糖尿病治療薬のサイエンス, 稲垣暢也編, pp.172-179, 南山堂, 東京, 2012.
 
12) Rossetti L, Smith D, Shulman GI et al : J Clin Invest 79 (5) : 1510-1515, 1987.
PubMed
13) Meng W, Ellsworth BA, Nirschl AA et al : Discovery of dapagliflozin : a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51 (5) : 1145-1149, 2008.
PubMed
14) Lam JT, Martin MG, Turk E et al : Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects. Biochim Biophys Acta. 1453 (2) : 297-303, 1999.
PubMed
15) Oku A, Ueta K, Arakawa K et al : T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48 (9) : 1794-1800, 1999.
PubMed
16) Chao EC, Henry RR : SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 9 (7) : 551-559, 2010.
PubMed
17) Washburn WN, Poucher SM : Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 22 (4) : 463-486, 2013.
PubMed
18) Nomura S, Sakamaki S, Hongu M et al : Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 53 (17) : 6355-6360, 2010.
 
19) Imamura M, Nakanishi K, Suzuki T et al : Discovery of Ipragliflozin (ASP1941) : a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem 20 (10) : 3263-3279, 2012.
 
20) Ohtake Y, Sato T, Kobayashi T et al : Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 55 (17) : 7828-7840, 2012.
 
21) Neumiller JJ, White JR Jr, Campbell RK : Sodiumglucose co-transport inhibitors : progress and therapeutic potential in type 2 diabetes mellitus. Drugs 70 (4) : 377-385, 2010.
PubMed
22) Lo MC, Lansang MC : Recent and Emerging Therapeutic Medications in Type 2 Diabetes Mellitus : Incretin-Based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. Am J Ther 20 (6) : 638-653, 2013.
PubMed
23) Santer R, Calado J : Familial renal glucosuria and SGLT2 : from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5 (1) : 133-141, 2010.
PubMed

【研究会】

P.113 掲載の参考文献
Tension pneumatocephalus after administration of two 0.25 mg cabergoline tablets in MEN-1 related pacroprolactinoma. Nanba K, Usui T, Nakakuki T, Shimatsu A. BMJ Case Rep. 2013 Jun 7.
 

【研究】

P.124 掲載の参考文献
1) 厚生労働省ホームページ : ノロウイルスに関するQ&A http://www.mhlw.go.jp/topics/syokuchu/kanren/yobou/040204-1.html
 
2) 大阪府立公衆衛生研究所ホームページ : 「大阪府全域におけるノロウイルス流行調査」研究 http://www.iph.pref.osaka.jp/infection/noro/noro.html
 
3) 大阪府立公衆衛生研究所ホームページ : エンテロウイルス関連情報 http://www.iph.pref.osaka.jp/kansen/entero/ent.html
 
4) Gehrke C, Steinmann J, Goroncy-Bermes P : Inactivation of feline calicivirus, a surrogate of norovirus (formerly Norwalk-like viruses), by different types of alcohol in vitro and in vivo. J Hosp Infect 56 (1) : 49-55, 2004.
PubMed
5) Doultree JC, Druce JD, Birch CJ et al : Inactivation of feline calicivirus, a Norwalk virus surrogate. J Hosp Infect 41 (1) : 51-57, 1999.
PubMed
6) Malik YS, Maherchandani S, Goyal SM : Comparative efficacy of ethanol and isopropanol against feline calicivirus, a norovirus surrogate. Am J Infect Control 34 (1) : 31-35, 2006.
PubMed
7) Duizer E, Bijkerk P, Rockx B et al : Inactivation of Caliciviruses. Appl Environ Microbiol 70 (8) : 4538-4543, 2004.
PubMed
8) Lages SLS, Ramakrishnan MA, Goyal SM : In-vivo efficacy of hand sanitisers against feline calicivirus : a surrogate for norovirus. J Hosp Infect 68 (2) : 159-163, 2008.
PubMed
9) 山崎謙治, 木村朝昭, 左近直美 他 : 各種アルコール系殺菌消毒薬のウイルス不活化試験. 医学と薬学 48 (3) : 441-446, 2002.
Medical*Online
10) 佐藤隆一, 和田英己, 滝沢真紀 他 : 各種アルコール系消毒薬の評価. 医学と薬学 49 (5) : 713-724, 2003.
Medical*Online
11) Whitehead K, McCue KA : Virucidal efficacy of disinfectant actives against feline calicivirus, a surrogate for norovirus, in a short contact time. Am J Infect Control 38 (1) : 26-30, 2010.
 
12) Gulati BR, Allwood PB, Hedberg CW et al : Efficacy of Commonly Used Disinfectants for the Inactivation of Calicivirus on Strawberry, Lettuce, and a Food-Contact Surface. J Food Protect 64 (9) : 1430-1434, 2001.
 
13) 野田雅博, 松田俊二, 小林正夫 : 消毒剤の殺ウイルス効果に関する検討-殺ウイルス効果に及ぼす血清蛋白の影響-. 感染症学雑誌74 (8) : 664-669, 2000.
 
14) 隈下祐一, 加藤由実, 高本一夫 他 : ノロウイルス代替のネコカリシウイルスおよび各種微生物に有効なエタノール製剤の開発. 防菌防黴 35 (11) : 725-732, 2007.
 
15) 小堺博 : 食品の殺菌手法-原理・特徴・現状・課題8 化学的手法 (5) 食品のアルコールによる殺菌. 防菌防黴36 (12) : 859-867, 2008.
 
16) 深尾正 : 食品の化学的保存技術13 各論4) その他 (2) アルコールの食品への利用について. 防菌防黴 37 (12) : 913-922, 2009.
 
17) 岡本一毅, 奥西淳二, 渡邉幸彦 他 : アルコール消毒薬のノンエンベロープウイルスに対する有効性改善策. 日本環境感染学会誌 25 (2) : 68-72, 2010.
 
18) 奥西淳二, 岡本一毅, 西原豊 他 : 新規アルコール手指消毒薬MR06B7の有効性評価. 薬学雑誌 130 (5) : 747-754, 2010.
 
19) 中川博雄, 松田淳一, 柳原克紀 他 : ゲル状速乾性手指消毒剤の適正な擦り込み量に関する検討. 日本環境感染学会誌 26 (1) : 8-12, 2011.
 
20) 嶽本智子, 小林寛伊, 大久保憲他 : 臨床現場を反映したアルコールラビングの定量的評価. 医療関連感染 4 (1) : 19-24, 2011.
 
21) 大久保憲 : 平成15年度厚生労働科学研究費補助金 (厚生労働科学特別研究事業) 分担研究報告書 国, 自治体を含めた院内感染対策全体の制度設計に関する緊急特別研究「医療施設における院内感染 (病院感染) の防止について」
 
22) WHO Guidelines on Hand Hygiene in Health Care http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf
 
23) 山本美紀, 休波茂子 : 看護師の手洗い行動および認識とその「ずれ」に関する検討. 日本赤十字看護学会誌 8 (1) : 1-10, 2008.
 

【薬剤】

P.133 掲載の参考文献
1) 福本恭子, 大石美也, 上野和行他 : ジェネリック医薬品に対する薬剤師および患者の意識調査. ジェネリック研究 2 : 162-170, 2009.
 
2) 柳川忠二 : ジェネリック医薬品の情報提供 -薬剤師より医師・看護師に向けて-. 薬局 55 (11) : 2890-2894, 2004.
Medical*Online
3) 一川暢宏, 嶺豊春, 佐々木均 : ジェネリック医薬品の安定供給体制 -病院薬剤師の立場より-. 薬局 55 (11) : 2880-2884, 2004.
Medical*Online
4) 大久保正 : ニカルジピン注射製剤の先発医薬品と後発医薬品中のニカルジピン分解物 (L-1) 含有量の違いに関する研究. 医療薬学 31 (2) : 121-124, 2005.
Medical*Online
5) 木村康浩, 柴田ゆうか, 木平建治 他 : 注射用塩酸リトドリン製剤の先発医薬品と後発医薬品における品質比較. 医療薬学 32 (7) : 667-672, 2006.
 
6) 上野和行, 福本恭子 : ベシル酸アムロジピン錠の製品・品質比較評価. 医学と薬学 60 (5) : 735-745, 2008.
Medical*Online
7) 福本恭子, 上野和行 : メトホルミン塩酸塩フィルムコーティング製剤の品質試験. ジェネリック研究 3 : 43-47, 2009.
 
8) 西岡豊, 京谷庄二郎, 宮野望 他 : 一包化調剤実施による錠剤・カプセル剤の安定性. 病院薬学 25 (4) : 385-392, 1999.
Medical*Online
9) 関屋昇, 阿部信貴, 武田和久 他 : オパルモン(R) 錠の加湿下での安定性改善II 分包包装品の安定性. 医療薬学 32 (6) : 482-488, 2006.
Medical*Online
10) 上野和行, 木村元範, 福本恭子 : 市販ピモベンダン製剤の苛酷条件下での安定性に関する検討. 診療と新薬 48 (7) : 694-699, 2011.
 
11) リピトール錠 5mg, リピトール錠 10mg 医薬品インタビューフォーム (改訂第22版)
 

【臨床報告】

P.142 掲載の参考文献
1) 日本糖尿病学会 : 糖尿病治療ガイド2012-2013 血糖コントロール目標改訂版, 文光堂, 東京, 2013.
 
2) 石井均 : 糖尿病薬物治療とQOL. 糖尿病医療学入門 -こころと行動のガイドブック, 医学書院, 東京, pp78-87, 2011.
 
3) Bradley C, Gamsu DS : Guidelines for encouraging psychological well-being : report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet Med 11 : 510-516, 1994.
 
4) 奥平真紀, 内潟安子, 岡田泰助 他 : 検診と治療中断が糖尿病合併症に及ぼす影響. 糖尿病 46 : 781-785, 2003.
 
5) 税所芳史, 伊藤裕 : 外来患者へのアンケート調査にみる糖尿病治療満足度と治療中断意思との関係. 糖尿病 55 : 768-773, 2012.
 
6) 石井均, 古家美幸, 飯降直男他 : インスリン治療に関する夜間QOL質問表 (ITR-QOLN) の臨床知見. 糖尿病 51 : 601-608, 2008.
 
7) Ishii H : Development and psychometric validation of the Diabetes Therapy-Related QOL (DTRQOL) questionnaire. J Med Econ 15 : 556-563, 2012.
PubMed
8) Bradley C : The diabetes treatment satisfaction questionnaire : DTSQ. In ; Handbook of Psychology and Diabetes : a guide to psychological measurement in diabetes research and practice. Harwood Academic Publishers, Switzerland, 1994.
 
9) 石井均, Bradley C, Riazi A et al : 糖尿病治療満足度質問表 (DTSQ) の日本語翻訳と評価に関する研究. 医学のあゆみ 192 : 809-814, 2000.
 
10) 稲垣暢也 : GLP-1受容体作動薬 持続性エキセナチド注射剤 ビデュリオン(R) 皮下注用 2mg. 医学と薬学 70 : 285-291, 2013.
Medical*Online
11) DeYoung MB, MacConell L, Sarin V et al : Encapsulation of exenatide in poly- (D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 13 : 1145-1154, 2011.
PubMed
12) 「ビデュリオン(R) 皮下注用 2mg」医療用医薬品製品情報概要
 
13) Ji L, Onishi Y, Ahn CW et al : Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Invest 4 : 53-61, 2013.
 
14) Onishi Y, Koshiyama H, Imaoka T et al : Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest 4 : 182-189, 2013.
 
15) アストラゼネカ社内資料
 
16) Inagaki N, Atsumi Y, Oura T et al : Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug (s) : results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther 34 : 1892-1908, 2012.
PubMed
17) Ishii H, Anderson JH Jr, Yamamura A et al : Improvement of glycemic control and quality-of-life by insulin lispro therapy : assessing benefits by ITR-QOL questionnaires. Diabetes Res Clin Pract 81 : 169-178, 2008.
PubMed
P.151 掲載の参考文献
1) Hohlfeld P, Costa JM et al : Prenatal diagnosis of congenital toxoplasmosis with a polymerase chain-reaction test on amniotic fluid. N Eng J Med 331 : 695-699, 1994.
 
2) 山田秀人, 西川鑑他 : 先天性トキソプラズマ, サイトメガロウイルス感染症に対する出生前医療. 産婦人科治療 101 (5) : 563-568, 2010.
Medical*Online
3) 川名尚, 小島俊行 : 母子感染, 第1版, 金原出版, 東京, 2011.
 
4) 矢野明彦 : 日本におけるトキソプラズマ症, 第1版, 九州大学出版会, 福岡, 2007.
 
5) 小島俊行, 菅野素子他 : トキソプラズマ. 産科と婦人科 7 (11) : 1662-1672, 2008.
 
6) Makiko Sakikawa, Shunichi Noda et al : Anti-Toxoplasma Antibody Prevalence, Primary Infection Rate, and Risk Factors in a Study of Toxoplasmosis in 4,466 Pregnant Women in Japan. Clincal and Vaccine Immunology 19 (3) : 365-367, 2012.
 

【Diagnosis】

P.159 掲載の参考文献
1) 坪内博仁, 熊田博光, 清澤研道他 : 免疫抑制・化学療法により発症するB型肝炎対策 -厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告-. 肝50 : 38-42, 2009.
 
2) 飯田健, 狩野吉康, 髭修平他 : 全自動化学発光免疫測定システムARCHITECT によるHBc抗体及びHBs抗体測定の有用性評価. Progress in Medicine 22 : 1037-1046, 2002.
 
3) 伊藤公子, 曽根伸治, 高橋孝喜 : ルミパルス1200によるHBs抗原, 抗HBs抗体測定試薬「ルミパルス II HBsAg」, 「ルミパルス II HBsAb」の検討. 医学と薬学 33 : 771-776, 1995.
 
4) 出口松夫, 細坪秀夫, 和泉由紀子 他 : マイクロパーティクルを固相とするEIA法による血中HBs抗体の測定. 日本臨床検査自動化学会誌 17 : 660-664, 1992.
 
5) 山下順香, 細坪秀夫, 出口松夫他 : Latex Photometric Immunoassayによる血中HBs抗体測定の基礎検討と臨床応用. 臨床検査機器・試薬 16 : 593-599, 1993.
 
6) 山内聡, 藤原優子, 増田美和子他 : イムノクロマトグラフ法を用いた, HBs抗原, 抗体測定試薬「エスプラインHBsAg, HBsAb」の開発. 生物試料分析 21 : 59-59, 1998.
 
7) 山下順香, 細坪秀夫, 出口松夫 他 : HBs抗体の定量測定と臨床応用. 日本臨床検査自動化学会誌 19 : 728-733, 1994.
 
P.166 掲載の参考文献
1) 黒木由夫, 高橋弘毅 : 肺サーファクタント. SRL宝函 23 (4) : 228-233, 2000.
 
2) 藤嶋卓哉, 本田泰人, 高橋弘毅 : 特発性間質性肺炎におけるサーファクタント蛋白質A (SP-A) の変動と局在およびその臨床的意義. 札幌医誌 66 (6) : 327-340, 1997.
 
3) 佐々木信一, 久田哲哉 : 各種呼吸器疾患における検討. 日胸 61 (2) : 134-144, 2002.
Medical*Online
4) 高橋弘毅, 白鳥正典, 大塚満雄 : 肺サーファクタント蛋白質 (SP-A, SP-D). 日本臨牀 67 (8) : 361-363, 2009.
 
5) 石川暢久, 河野修興 : 間質性肺炎のマーカー - KL-6, SP-A, SP-D. 診断と治療 97 (9) : 1773-1777, 2009.
Medical*Online
6) 高橋弘毅, 白鳥正典, 千葉弘文 : SP-D, SP-A (IPFのバイオマーカー). 呼吸器内科 19 (6) : 597-604, 2011.
 
7) 阿部庄作, 本田泰人, 安藤正幸他 : 各種肺疾患における血清肺サーファクタント蛋白質-Aの臨床的意義. 日胸疾会誌 33 (11) : 1219-1225, 1995.
 

書評

最近チェックした商品履歴

Loading...